Singapore Institute of Advanced Medicine Holdings Ltd

Operates a single-site Singapore medical centre built around advanced imaging and radiation oncology. Two reported segments: medical diagnostics and treatments (cancer diagnostics, nuclear medicine, general health screening, aesthetic services) and radiation therapy and medical oncology (proton beam therapy, photon radiation therapy, medical oncology). Its stated clinical focus spans cancer, neurodegenerative and cardiovascular disease detection. The longevity-relevant part is the diagnostics and imaging arm: high-resolution and nuclear-medicine imaging plus paid health screening is early-detection infrastructure, the same category as preventive screening plays. The proton-beam oncology business is treatment for existing disease, not a longevity intervention, and is the larger capital commitment. There is no geroscience, biomarker-of-ageing, or therapeutic-development activity here. It is a small, loss-making clinical operator: FY2025 revenue SGD 15.71m, down 5.6% year on year, with a net loss of SGD 27.05m, and a market capitalisation under SGD 50m. Note the corporate site www.sam.com.sg did not resolve on repeated attempts, so the business description above rests on exchange-data aggregators rather than company disclosure.

Recent inflection

What moved lately